

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 May 2018 (24.05.2018)

(10) International Publication Number
WO 2018/093950 A1

(51) International Patent Classification:

A61K 31/445 (2006.01) C07D 295/182 (2006.01)
C07D 213/55 (2006.01)

(21) International Application Number:

PCT/US2017/061871

(22) International Filing Date:

15 November 2017 (15.11.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/423,124 16 November 2016 (16.11.2016) US
62/545,857 15 August 2017 (15.08.2017) US

(71) Applicant: ABIDE THERAPEUTICS, INC. [US/US];
10835 Road to the Cure, Suite 250, San Diego, California
92121 (US).

(72) Inventors: GRICE, Cheryl A.; 924 Springwood Lane,
Encinitas, California 92024 (US). WHITE, Nicole S.; 3672
Caminito Cielo Del Mar, San Diego, California 92130 (US).
ZINGERMAN, Joel P.; 1712 Catalpa Road, Carlsbad, Cal-
ifornia 92011 (US). TEREFE, Hibreniguss; 1320 Pow-
derhorn Place, Piscataway, New Jersey 08876 (US). GHE-
BRE-SELLASSIE, Isaac; 21 Meadow Bluff Road, Morris
Plains, New Jersey 07950 (US).

(74) Agent: HOSTETLER, Michael J.; WILSON SONSINI
GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto,
California 94304 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: PHARMACEUTICAL FORMULATIONS

(57) Abstract: Provided herein are pharmaceutical formulations comprising a monoacylglycerol lipase (MAGL) inhibitor, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

